A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
Latest Information Update: 10 Feb 2025
At a glance
- Drugs COH 29 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 06 Feb 2025 Planned End Date changed from 31 Dec 2024 to 20 Jun 2025.
- 29 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.